ELIXF (Elixxer) Buyback Yield %: 0.00 (As of Jun. 30, 2026)


What is Elixxer Buyback Yield %?

Elixxer ELIXF Buyback Yield % is 0.00 as of Jun. 30, 2026. The stock has 1 warning sign investors should review. Among 292 Drug Manufacturers companies, Elixxer ranks worse than 342465.41% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Elixxer's current buyback yield was 0.00%.

Elixxer Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Elixxer's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elixxer Buyback Yield % Chart

Elixxer Annual Data
Trend Jun15 Jun16 Sep17 Sep18 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 4.72 0.00 0.00 0.00

Elixxer Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ELIXF vs ZTS, UTHR: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elixxer's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elixxer Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elixxer's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Elixxer's Buyback Yield % falls into.


Elixxer Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Elixxer's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 0) / 0.1269968
=0.00%

Elixxer's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 0) / 0.1269968
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of 0.00 mean?
Elixxer (ELIXF) has a Buyback Yield % of 0.00 as of Jun. 30, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Elixxer and its competitors. According to the industry distribution chart, Elixxer ranks #999999 out of 292 companies in the Drug Manufacturers industry.
Is Elixxer's Buyback Yield % too high?
Elixxer's current Buyback Yield % is 0.00. Based on the distribution chart, Elixxer ranks #999999 out of 292 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Elixxer's Buyback Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Elixxer ranks #999999 out of 292 companies for Buyback Yield %. This places Elixxer in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Elixxer and its competitors. Elixxer's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixxer stock overvalued right now?
Elixxer (ELIXF) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Elixxer (ELIXF), the current Buyback Yield % is 0.00 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elixxer Business Description

Other Exchanges ELXR.H:Canada
Address 200 Bay Street, Suite 3240, Royal Bank Plaza, South Tower, Toronto, ON, CAN, M5J 2J1
Elixxer Ltd is a Canada-based cannabis investment firm in the legal cannabis market. It invests in cannabis-related businesses that are fully licensed for the cultivation, production, and sale of cannabis and cannabis-derived products.